CoChat

Considerations for Pharmacoepidemiological Studies of Drug–Cancer Associations

Open access
Pottegård, Anton, Friis, Søren, Stürmer, Til, Hallas, Jesper, Bahmanyar, Shahram · 2018 · Basic & Clinical Pharmacology & Toxicology
Cited by 101

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

In this MiniReview, we provide general considerations for the planning and conduct of pharmacoepidemiological studies of associations between drug use and cancer development. We address data sources, study design, assessment of drug exposure, ascertainment of cancer outcomes, confounder adjustment and future perspectives. Aspects of data sources include assessment of complete history of drug use and data on dose and duration of drug use, allowing estimates of cumulative exposure. Outcome data from formal cancer registries are preferable, but cancer data from other sources, for example, patient or pathology registries, medical records or claims are also suitable. The two principal designs for observational studies evaluating drug–cancer associations are the cohort and case–control designs. A key challenge in studies of drug–cancer associations is the exposure assessment due to the typically long period of cancer development. We present methods to examine early and late effects of drug use on cancer development and discuss the need for employing ‘lag‐time’ in order to avoid reverse causation. We emphasize that a new‐user study design should always be considered. We also underline the need for ‘dose–response’ analyses, as drug–cancer associations are likely to be dose‐dependent. Generally, studies of drug–cancer associations should explore risk of site‐specific cancer, rather than cancer overall. Additional differentiation may also be crucial for organ‐specific cancer with various distinct histological subtypes (e.g., lung or ovary cancer). We also highlight the influence of confounding factors and discuss various methods to address confounding, while emphasizing that the choices of methods depend on the design and specific objectives of the individual study. In some studies, use of active comparator(s) may be preferable. Pharmacoepidemiological studies of drug–cancer associations are expected to evolve considerably in the coming years, due to the increasing availability of long‐term data on drug exposures and cancer outcomes, the increasing conduct of multinational studies, allowing studies of rare cancers and subtypes of cancer, and methodological improvements specifically addressing cancer and other long‐term outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bcpt.12946

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 101

Metadata

Authors
Pottegård, A., Friis, S., Stürmer, T., Hallas, J., & Bahmanyar, S.
Venue
Basic & Clinical Pharmacology & Toxicology
Publisher
Wiley
Published
2018-01-15
Volume
122
Issue
5
Pages
451-459
ISSN
  • 1742-7835 (ISSN-L)
  • 1742-7843
OpenAlex
W2778435052
Cited by
101
References
16
FWCI
3.34
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Considerations for Pharmacoepidemiological Studies of Drug–Cancer Associations. https://app.cochat.ai/papers/10.1111/bcpt.12946
The paper
Pottegård, A., Friis, S., Stürmer, T., Hallas, J., & Bahmanyar, S. (2018). Considerations for Pharmacoepidemiological Studies of Drug–Cancer Associations. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.12946

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.